Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) – Investment analysts at Jefferies Group cut their FY2017 EPS estimates for shares of Hikma Pharmaceuticals in a research report issued on Monday. Jefferies Group analyst J. Vane-Tempest now anticipates that the company will earn $0.88 per share for the year, down from their prior estimate of $0.92. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Hikma Pharmaceuticals’ FY2018 earnings at $0.81 EPS, FY2019 earnings at $0.85 EPS, FY2020 earnings at $0.96 EPS and FY2021 earnings at $1.03 EPS.
Other analysts have also issued reports about the stock. Morgan Stanley restated an “equal weight” rating on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 8th. Zacks Investment Research lowered shares of Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Finally, Goldman Sachs Group lowered shares of Hikma Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold”.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.